in5points
FinanceNDTV

Dr. Lal Gets Higher Target Price After Robust Q1, Yet ICICI Securities Downgrades Rating

in5points

  1. Dr. Lal PathLabs received a higher target price from ICICI Securities after robust Q1 results.

  2. ICICI Securities downgraded the rating, citing uncertainty about sustained growth into Q2 FY27.

  3. The brokerage noted strong growth for the last two quarters but flagged a potential trend change.

2h ago · original ↗
Dr. Lal Gets Higher Target Price After Robust Q1, Yet ICICI Securities Downgrades Rating · in5points